Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXS74539 in Select Solid Tumors
NCT07517198Phase 1Recruiting
- Sponsor
- Exscientia
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of REC-4539 in solid tumor, small cell lung cancer (SCLC), neuroendocrine cancer and 9 more, sponsored by Exscientia. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events at 3 years, Dose-limiting Toxicity at 28 days and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
REC-4539
03
Conditions
solid tumorsmall cell lung cancer (SCLC)neuroendocrine cancersmall cell carcinoma (SCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07517198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517198.